Zhejiang Jingxin Pharmaceutical Co Ltd (002020.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE000001K73
Zhejiang Jingxin Pharmaceutical Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 4.16 bn CNY | 4.07 bn CNY |
| Gross profit | 2.06 bn CNY | 2.04 bn CNY |
| Operating income | 843.61 m CNY | 844.79 m CNY |
| EBIT | 714.56 m CNY | 868.28 m CNY |
| Net income | 711.96 m CNY | 757.98 m CNY |
| Diluted EPS – continuing operations | 0.83 CNY | 0.88 CNY |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemihydrate, levofloxacin hydrochloride, levofloxacin lactate, enrofloxacin, enrofloxacin hydrochloride, simvastatin, rosuvastatin calcium, pitavastatin calcium, ticagrelor, rivaroxaban, apixaban, cisapride, levetiracetam, brivaracetam, sertraline HCI, rivastigmine bitartrate, pramipexole dihydrochloride, memantine hydrochloride, empagliflozin, dapagliflozin, marbofloxacin, and moxifloxacin. It also provides intermediates; and medical display products, such as diagnostic medical displays, endoscopy, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, medical imaging solutions, ultrasonic medical displays, and other products. The company was formerly known as Zhejiang Jingxin Pharmaceutical Factory and changed its name to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000. Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1990 and is headquartered in Xinchang, China.
More stocks
- Triumph Financial, Inc. (TFIN)
- Fila Holdings Corp (081660.KS)
- ShenZhen QiangRui Precision Technology Co. Ltd. (301128.SZ)
- Bellevue Gold Ltd (BGL.AX)
- Premier Energy (PE.RO)
- Shiny Chemical Industrial Co Ltd (1773.TW)
- Tenaz Energy Corp (TNZ.TO)
- MasterBrand, Inc. (MBC)
- Jingbo Technology, Inc. (SVMB)
- CAPITAL SOUTHWEST CORP (CSWC)
- NETSTREIT Corp. (NTST)
- Neusoft Corp (600718.SS)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.